21.218 articles found

Xanthine-Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases.

Załuski M, Karcz T, Drabczyńska A, Vielmuth C, Olejarz-Maciej A, Głuch-Lutwin M, Mordyl B, Siwek A, Satała G, Müller CE, Kieć-Kononowicz K.

Biomolecules · 2023-07-05

DOI: 10.3390/biom13071079PMID: 37509114

Dopamine agonist therapy in Parkinson's disease: Spanish expert consensus on its use in different clinical situations.

Santos García D, Pagonabarraga Mora J, Escamilla Sevilla F, García Ruiz PJ, Infante Ceberio J, Kulisevsky Bojarski J, Linazasoro Cristóbal G, Luquín Piudo MR, Martínez Castrillo JC, Jesús Maestre S, Vela Desojo L, Campos Lucas FJ, Caballero Martínez F, Mir P, Panel of Experts Phase 1.

Neurologia (Engl Ed) · 2023-07-05

DOI: 10.1016/j.nrleng.2023.04.008PMID: 37419211

Editorial: New technologies for detection, monitoring and treatment of Parkinson's disease, volume II.

Mirian MS, Lee S, McKeown MJ.

Front Aging Neurosci · 2023-07-04

DOI: 10.3389/fnagi.2023.1235265PMID: 37469952

The risk of developing motor complications with Levodopa immediate versus dual release upon treatment initiation in Parkinson's disease.

Ineichen C, Baumann-Vogel H, Sitzler M, Baumann CR.

Clin Park Relat Disord · 2023-07-04

DOI: 10.1016/j.prdoa.2023.100209PMID: 38107673

Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson's disease.

Richmond AM, Lyons KE, Pahwa R.

Expert Opin Drug Saf · 2023-07-04

DOI: 10.1080/14740338.2023.2227096PMID: 37401865

Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson's disease.

Su D, Zhang X, Su Y, Chan P, Xu E.

Heliyon · 2023-07-04

DOI: 10.1016/j.heliyon.2023.e17876PMID: 37483692

Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.

ZhuParris A, Thijssen E, Elzinga WO, Makai-Bölöni S, Kraaij W, Groeneveld GJ, Doll RJ.

Mov Disord · 2023-07-04

DOI: 10.1002/mds.29520PMID: 37401265

Type, Timing, Frequency, and Durability of Outcome of Physical Therapy for Parkinson Disease: A Systematic Review and Meta-Analysis.

El Hayek M, Lobo Jofili Lopes JLM, LeLaurin JH, Gregory ME, Abi Nehme AM, McCall-Junkin P, Au KLK, Okun MS, Salloum RG.

JAMA Netw Open · 2023-07-03

DOI: 10.1001/jamanetworkopen.2023.24860PMID: 37477916

Network analysis of the whole body kinematics in Parkinson diseases following levodopa intake

Romano A, Liparoti M, Minino R, Polverino A, Cipriano L, Ciaramella F, Carotenuto A, Tafuri D, Sorrentino G, Sorrentino P, Lopez ET.

· 2023-07-01

DOI: 10.1101/2023.06.29.23292021

Clinical characteristics and reaction to dopaminergic treatment of drug-naïve patients with Parkinson's disease in central China: A cross sectional study

Zeng W, Wang Y, Liu L, Wu Y, Xu Y, Zhai H, Yang X, Cao X, Xu Y.

Heliyon · 2023-07-01

Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson's disease

Su D, Zhang X, Su Y, Chan P, Xu E.

Heliyon · 2023-07-01

Foslevodopa-Foscarbidopa (Vyalev): CADTH Reimbursement Recommendation: Indication: For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products

Check source for author details

· 2023-07-01

PMID: 37782736